MedPath

Evaluation of the efficacy of romosozumab for hemodialysis patients with hemodialysis

Not Applicable
Conditions
osteoporosis
Registration Number
JPRN-UMIN000039889
Lead Sponsor
Showa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who are not receiving standard treatment for osteoporosis 2)Persons who are contraindicated in taking evenity or denosumab 3)Patients who have taken romosozumab or denosumab within 6 months 4)Hypocalcemia 5)Patients with severe liver dysfunction, heart dyfunction, malignant tumor 6)Patients who are judged by the investigator not to be eligible for drug administration.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath